戻る Agenda
Session 3 - The Second Impact of ICH and Its Impact on the Operations in Japan
Session Chair(s)
Mitsuo Hayashi, MSC, RPH
Director & Head, Clinical Enablement
MSD K.K., Japan
Toshiko Ishibashi, PHD, RN
Oncology Medical Science Department, Medical Affairs Division
Daiichi Sankyo Co., Ltd., Japan
Speaker(s)
New Concepts in the E9 (R1) Guideline
Hideki Suganami, PHD
Kowa Company, Ltd., Japan
Global Data Science Center, Head
Will the E17 Guideline Change the Conduct of Multi-Regional Clinical Trials (MRCTs)?
Takahiro Araki, MD, PHD
Takeda Pharmaceutical Company Limited, Japan
Senior Clinical Science Director, Takeda Development Center Japan